BICARA THERAPEUTICS INC (BCAX)
Health Care · biotechnology / oncology · NASDAQ
Bicara Therapeutics is developing a pipeline of bifunctional antibodies that precisely target and neutralize both EGFR and TGF-β pathways to improve treatment outcomes in solid tumors.
What BICARA THERAPEUTICS INC does
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. The company's lead program, ficerafusp alfa, is a bifunctional monoclonal antibody that combines EGFR targeting with a TGF-β ligand trap, designed to enhance drug delivery to the tumor microenvironment while limiting systemic toxicity. Ficerafusp alfa simultaneously blocks cancer cell EGFR survival pathways and immunosuppressive TGF-β signaling to drive immune cell infiltration and anti-tumor responses. The company is advancing ficerafusp alfa in clinical trials for head and neck squamous cell carcinoma and other solid tumors with inadequate tumor penetration and strong biologic rationale for dual EGFR/TGF-β inhibition.
Themes: oncology, bifunctional therapies, EGFR inhibitors, TGF-β signaling inhibition, solid tumors, immunotherapy
Fundamentals
- Price$23.58 as of 2026-08-24 close
- Market cap$1.6B as of 2026-08-24
- 1-year return+99.2% 2025-08-22 close $11.84 → 2026-08-24 close $23.58
- P/En/a earnings data not available
- ROE-35.9% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta1.42 as of 2026-08-24
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How BCAX compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How BICARA THERAPEUTICS INC looks technically
BICARA THERAPEUTICS INC (BCAX) is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 206 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 7 trading days ago. It is 22.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 17.5% above its 200-day average, the long-term trend line — a longer-term uptrend | +17.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $26.36 | $26.36 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $20.34 | $20.34 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 10 calendar days ago — the swings before that are what the structure reading is measured on | 10 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 26.64. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 206 trading days ago — a "golden cross", a bullish long-term signal | 206 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 26, with sellers in control | 26.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 42, neither overbought (above 70) nor oversold (below 30) | 41.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($22.80 to $28.43) — its "stochastic" reading is 20 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 19.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 29 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $30.99 | $30.99 |
|---|---|---|
| From the 52-week high | it is 22.9% below its 52-week high (its highest price of the past year) | -22.9% |
| Above the 52-week low | it is 149.7% above its 52-week low (its lowest price of the past year) | +149.7% |
| Below the 52-week high | it is 22.9% below its highest point of the past year | 22.9% |
| Since a 20-day breakout | it made a new 20-day low about 7 trading days ago | 7 sessions |
| Since a 55-day breakout | it made a new 55-day high about 34 trading days ago | 34 sessions |
| All-time high | its highest closing price on record is $30.99 (set on 2026-07-07) | $30.99 |
| Given back of the 52-week move | over the past year its closes ranged ($9.99 to $30.40), and it has given back roughly a third of its rise from last year’s low — 32% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.13 to $17.79. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 31.9% |
| From the all-time high | it is 22.9% below its all-time high | -22.9% |
| Nearest price level | it is trading 4.9% above a support level at $22.74 — a price it turned at twice since 2024-12-09, most recently on 2026-08-11. Since 2024-09-13 it has 10 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -4.9% |
| All-time low | its lowest closing price on record is $7.80 (set on 2025-05-23) | $7.80 |
| Above the all-time low | it is 206.4% above its all-time low | +206.4% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 41st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.60 between its high and its low — about 6.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.60 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $22.99 and $28.54 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $22.99 – $25.76 – $28.54 |
| Typical daily range (% of price) | its price moves about 6.7% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.7% |
| Stretch from the 200-day average | it is trading 2.2 daily ranges above its 200-day average price (17.5% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.85× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 6.1% since the prior reading | +6.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.04 toward sell |
Candlestick patterns
2
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 1.4% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +1.4% |
|---|---|---|
| Open gap | it gapped 17.8% below the previous close 8 sessions ago and has not traded back through the level it left behind at 27.73 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -17.8% |
| Gap filled | a 4.7% gap up opened on 2026-08-19 has been "filled" 1 session ago — price traded back through the level the gap left behind, and it took 1 session to close | 1 session ago |
Price streaks
1
| Closing streak | it has closed lower 2 sessions in a row, a -7.58% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 2 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 17.4 percentage points (the stock lost 15.1% while the market gained 2.3%) | -17.4% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 11.6 percentage points (the stock gained 14.7% while the market gained 3.1%) | +11.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 43.3 percentage points (the stock gained 54.4% while the market gained 11.1%) | +43.3% |
| vs market, 12 months | over the past 12 months this stock beat the market by 85.0 percentage points (the stock gained 105.5% while the market gained 20.5%) | +85.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.9% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -3.6% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 7% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $22.31 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | +7.1% |
|---|
Price levels it has turned at before
BCAX last closed at $23.90 on 2026-08-21. Since 2024-09-13 it has turned at 10 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $22.74 | Support | 4.9% below the last close | turned there twice · 2024-12-09 to 2026-08-11 |
| $19.71 | Support | 17.5% below the last close | turned there three times · 2024-12-26 to 2025-12-11 |
| $28.26 | Resistance | 18.2% above the last close | turned there twice · 2024-11-06 to 2026-08-07 |
| $18.32 | Support | 23.4% below the last close | turned there three times · 2024-10-11 to 2026-01-22 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $26.64.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $24.24 and $25.86 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $22.80.
This reading has stood for 3 trading days, since 2026-08-19.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · Analyst price target recently RAISED · beating the market · Most volatile (6%+ typical daily range) · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.64 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$33.38 range $20.00 – $45.00; median $34.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for BCAX
- Consensus EPS estimate-$0.8254 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Highly dependent on the clinical success and regulatory approval of its lead candidate, ficerafusp alfa.","Significant capital requirements and operating losses associated with clinical-stage pharmaceutical development.","Potential for clinical trial delays or failure to achieve desired primary endpoints for accelerated approval."]
What changed in the latest 10-Q
AI-assisted comparison of BCAX's 10-Q filed 2026-05-11 against the prior one filed 2025-11-10.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing describes the platform as designed to 'facilitate the development of bifunctional therapies that precisely target the tumor and deliver a tumor-modulating payload to the tumor site' (filed 2026-05-11)
- Newer filing states ficerafusp alfa is 'formerly BCA101' (filed 2026-05-11)
- Newer filing includes detailed explanation that ficerafusp alfa 'directs the TGF-β inhibitor into the immediate TME through the binding of EGFR on tumor cells' (filed 2026-05-11)
- Newer filing adds specific focus on 'head and neck cancers and other squamous cell carcinomas which typically overexpress EGFR and TGF-β pathways' (filed 2026-05-11)
- Newer filing adds statement about focusing 'efforts and resources on the continued development of ficerafusp alfa in those tumor types for which there is strong biologic rationale and remaining unmet need for enhanced tumor penetration' (filed 2026-05-11)
- Newer filing reports January 2026 announcement that '1500mg QW of ficerafusp alfa was selected as the optimal dose' for Phase 3 (filed 2026-05-11)
- Newer filing reports February 2026 completion of 'transition to the Phase 3 portion of the FORTIFI-HN01 trial' (filed 2026-05-11)
- Newer filing adds enrollment milestone: 'We enrolled the first patients in the FORTIFI-HN01 trial in February 2025' (filed 2026-05-11)
- Newer filing adds timeline expectation: 'We expect to achieve substantial enrollment by the end of 2026 to enable an interim analysis in mid-2027 to support potential accelerated approval and U.S. launch in 2028' (filed 2026-05-11)
- Newer filing adds section on 'Alternate dose study' evaluating '2000mg of ficerafusp alfa every-other-week' with loading and maintenance regimen (filed 2026-05-11)
- Newer filing reports February 2026 presentation of 'positive data from the Phase 1b expansion cohort evaluating 2000mg of ficerafusp alfa every-other-week' at 2026 Multidisciplinary Head and Neck Cancers Symposium (filed 2026-05-11)
- Newer filing describes FDA discussions and plan to 'initiate a randomized clinical study' with loading dose of 1500mg QW followed by 2250mg every three weeks (filed 2026-05-11)
- Newer filing states expectation to 'initiate the study in the third quarter of 2026' (filed 2026-05-11)
- Newer filing reports May 2026 peer-reviewed publication in Journal of Clinical Oncology (filed 2026-05-11)
- Newer filing specifies March 20, 2025 data snapshot for Phase 1b results (filed 2026-05-11)
- Newer filing adds statement about three-year follow-up data planned for 2026 ASCO Annual Meeting (filed 2026-05-11)
- Newer filing adds expansion cohort for 'HPV-negative HNSCC with CPS<1' (filed 2026-05-11)
- Newer filing adds expansion cohort for 'HPV-positive smokers HNSCC' (filed 2026-05-11)
- Newer filing adds expansion cohorts in 'third-line metastatic colorectal cancer with microsatellite stable RAS/BRAF wild-type' (filed 2026-05-11)
- Newer filing includes section on 'Chief Medical Officer transition and appointment of Chief Commercial Officer' effective May 8, 2026 (filed 2026-05-11)
- Newer filing states Bill Schelman, M.D., Ph.D. 'succeeded David Raben, M.D.' as Chief Medical Officer (filed 2026-05-11)
- Removed:
- Older filing described ficerafusp alfa as 'potential first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment' (filed 2025-11-10)
- Older filing used phrasing 'Through this dual-targeting mechanism, ficerafusp alfa may reverse the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling' (filed 2025-11-10)
- Older filing stated trial exclusion criteria as 'excluding patients with HPV-positive oropharyngeal squamous cell carcinoma, or OPSCC' (filed 2025-11-10)
- Older filing stated 'We initiated a pivotal FORTIFI-HN01 Phase 2/3 trial...in the fourth quarter of 2024' (filed 2025-11-10)
- Older filing included substantial financial and operational discussion with specific metrics on cash raised ($688.3 million), cash position ($407.6 million as of September 30, 2025), and net losses ($36.3 million and $100.6 million for specific periods) (filed 2025-11-10)
- Older filing included statement about sufficiency of funds 'into the first half of 2029' (filed 2025-11-10)
- Older filing included detailed discussion of funding strategy and capital raising needs (filed 2025-11-10)
- Older filing included 'Phase 1/1b Clinical Trial Highlights' section with specific efficacy data: ORR 54%, deep response 80% of responders, median duration of response 21.7 months, median OS 21.3 months, 2-year OS rate 46% (filed 2025-11-10)
- Reworded:
- Older filing: 'Our lead program ficerafusp alfa is a potential first-in-class bifunctional antibody'; Newer filing: describes it as part of 'We have built a platform designed to facilitate the development of bifunctional therapies' with more emphasis on platform approach (filed 2026-05-11 vs 2025-11-10)
- Older filing: 'ficerafusp alfa combines two clinically validated targets, an epidermal growth factor receptor...with a domain that binds to human transforming growth factor beta'; Newer filing: 'a bifunctional epidermal growth factor receptor-, or EGFR, directed monoclonal antibody bound to a human transforming growth factor beta, or TGF-β, ligand trap' - uses 'ligand trap' terminology (filed 2026-05-11 vs 2025-11-10)
- Older filing: described study population as excluding HPV-positive OPSCC patients; Newer filing: specifies inclusion criteria as 'HPV-negative head and neck squamous cell carcinoma' with 'combined positive score, or CPS, of ≥1' (filed 2026-05-11 vs 2025-11-10)
- Older filing: refers to 'at least 24 months of follow-up'; Newer filing: refers to 'March 20, 2025 data snapshot' and planned 'three-year follow-up data' (filed 2026-05-11 vs 2025-11-10)
- Notes:
- The older filing text appears to be truncated at the end ('Ficerafusp alfa 1500mg weekly and 750mg weekly are both currently being explored i'), which may indicate missing content in the source document
- The newer filing text also appears to be truncated mid-sentence ('On May 8, 2026, Bill Schelman, M.D., Ph.D., previously our Executive Vice President, Clinical Development, succeeded David Raben, M.D. to serve as our Chief Med'), limiting the ability to fully assess that section
- The older filing included significant financial sections that are not present in the newer filing excerpt, making it unclear whether financial discussions were removed or simply not included in the provided text
Risk Factors
- Added:
- Reference to 'the February 2026 Offering' as a funding source (newer filing, 2026-05-11)
- Statement that 'we may in the future fund operations through additional sales of our securities' with emphasis on 'additional' (newer filing, 2026-05-11)
- Removed:
- Reference to 'our preclinical and clinical development' changed to only 'clinical development' (older filing, 2025-11-10 had more specific language)
- Three-month and nine-month net loss figures for September 30, 2025 and 2024 ($36.3M, $17.5M, $100.6M, $47.0M) removed (older filing, 2025-11-10)
- Statement 'As of September 30, 2025, we have not yet generated revenues' removed (older filing, 2025-11-10)
- Phrase 'and market development' changed to 'as we expand our market development' (wording reorganization)
- Headcount language changed from 'as we expand our research and development organization and market development and pre-commercial planning activities' to 'as we expand our market development and pre-commercial planning activities' (research and development organization reference removed)
- Reworded:
- Net loss figures updated from three months ended September 30, 2025/2024 to three months ended March 31, 2026/2025 ($56.2M and $36.8M respectively) (newer filing, 2026-05-11)
- Reference date changed from 'As of September 30, 2025' to 'As of March 31, 2026' (newer filing, 2026-05-11)
- Introductory phrase to funding sources changed from 'To date, we have funded our operations principally through our IPO and private financings' to 'To date, we have funded our operations principally through our initial public offering, or our IPO, our ATM Program (as defined below), the February 2026 Offering (as defined below), and private financings' (newer filing, 2026-05-11)
- Capital raising risk heading changed from 'We will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.' to 'If we are unable to raise capital when needed, or on acceptable terms, we may be unable to complete the development and commercialization of ficerafusp alfa or any future product candidates.' (newer filing, 2026-05-11)
- Closing development description revised from 'commence additional' to 'continue to develop and deploy our bifunctional approach, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acqu' (text truncated in both versions but wording differs)
- Notes:
- Newer filing text appears truncated at end; full comparison of final paragraph not possible
- Older filing text also appears truncated at end; full comparison of final paragraph not possible
- Some formatting differences may reflect section breaks rather than substantive changes
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 12 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 3 sells ($1M) — 3 selling insiders
- Last 90 days0 buys · 12 sells ($3M) — 3 selling insiders
- Last 180 days0 buys · 22 sells ($5M) — 4 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-10. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about BCAX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding BCAX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 8,090,266
- Reported value $160,915,386
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
BCAX had 9,597,404 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
BCAX had 14.5% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 20.42 days to cover at the same settlement.
- Reported short interest (shares) 9,597,404
- Short interest (% of shares outstanding) 14.5%
- Prior settlement (shares) 9,315,906
- Reported change 3.02%
- Days to cover (reported) 20.42
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Merck (MRK)
- AstraZeneca (AZN)
- Bristol Myers Squibb (BMY)
- Eli Lilly (LLY)
- Genentech (Roche)
- Amgen (AMGN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare BCAX vs…
BICARA THERAPEUTICS INC is found in…
Frequently asked questions
What does BICARA THERAPEUTICS INC (BCAX) do?
Bicara Therapeutics is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. The company's lead program, ficerafusp alfa, is a bifunctional monoclonal antibody that combines EGFR targeting with a TGF-β ligand trap, designed to enhance drug delivery to the tumor microenvironment while limiting systemic toxicity.
What sector is BICARA THERAPEUTICS INC (BCAX) in?
BICARA THERAPEUTICS INC (BCAX) is classified in the Health Care sector. Its industry is biotechnology / oncology. It trades on NASDAQ.
Who are BICARA THERAPEUTICS INC's (BCAX) competitors?
Notable peers of BICARA THERAPEUTICS INC (BCAX) include Merck, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Genentech (Roche). This peer set is informational only — not financial advice.
Is BICARA THERAPEUTICS INC (BCAX) overbought or oversold right now?
BICARA THERAPEUTICS INC (BCAX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 42, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on BCAX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.